

ACORDA THERAPEUTICS INC  
Form 10-Q  
August 14, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**  
**For the quarterly period ended June 30, 2006**  
**OR**  
☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 000-50513

---

**ACORDA THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of incorporation)

**13-3831168**  
(I.R.S. Employer identification number)

**15 Skyline Drive  
Hawthorne, New York 10532**

(914) 347-4300

(Address, including zip code, and telephone number,  
including area code, of registrant's principal executive offices)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class  
Common Stock, \$0.001 par value per share

Outstanding at June 30, 2006  
19,630,636 shares



ACORDA THERAPEUTICS, INC.

TABLE OF CONTENTS

**PART I FINANCIAL INFORMATION**

<u>Item 1.</u>	<u>Financial Statements</u>	
	<u>Consolidated Balance Sheets</u>	
	<u>June 30, 2006 (unaudited) and December 31, 2005</u>	3
	<u>Consolidated Statements of Operations (unaudited)</u>	
	<u>Three and six-month periods ended June 30, 2006 and 2005</u>	6
	<u>Consolidated Statements of Cash Flows (unaudited)</u>	
	<u>Six-month period ended June 30, 2006 and 2005</u>	7
	<u>Notes to Consolidated Financial Statements (unaudited)</u>	8
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	17
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risks</u>	31
<u>Item 4.</u>	<u>Controls and Procedures</u>	31
	<b><u>PART II OTHER INFORMATION</u></b>	
<u>Item 1.</u>	<u>Legal Proceedings</u>	II-1
<u>Item 6.</u>	<u>Exhibits</u>	II-1

*This Quarterly Report on Form 10-Q contains forward-looking statements relating to future events and our future performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Stockholders are cautioned that such statements involve risks and uncertainties. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's beliefs and assumptions. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipates, believes, estimates, expects, intends, may, plans, projects, will, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this report and in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2005 and Form 10-Q for the three-month period ended March 31, 2006, particularly in the Risk Factors section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any forward-looking statements.*

**PART I****Item 1. Financial Statements****ACORDA THERAPEUTICS, INC. AND SUBSIDIARY****Consolidated Balance Sheets**

	<b>June 30, 2006 (unaudited)</b>	<b>December 31, 2005</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 23,684,368	\$ 11,761,299
Restricted cash	267,430	262,993
Short-term investments	500,135	2,001,175
Trade accounts receivable, net	1,195,933	589,252
Grant receivable	223,876	155,178
Prepaid expenses	1,366,557	2,224,042
Finished goods inventory held by the Company	6,244,667	5,586,842
Finished goods inventory held by others	1,106,476	1,170,603
Other current assets	1,754,531	1,712,550
Total current assets	36,343,973	25,463,934
Property and equipment, net of accumulated depreciation	1,481,697	1,707,104
Intangible assets, net of accumulated amortization	5,582,738	5,952,261
Other assets	784,291	788,531
Total assets	\$ 44,192,699	\$ 33,911,830
<b>Liabilities, Mandatorily Redeemable Convertible Preferred Stock and Stockholders (Deficit)</b>		
Current liabilities:		
Accounts payable	\$ 2,944,137	\$ 4,133,611
Accrued expenses and other current liabilities	3,346,695	9,926,773
Accrued product returns		1,831,211
Deferred product revenue Zanaflex tablets	8,480,880	11,509,598
Deferred product revenue Zanaflex Capsules	5,830,531	5,226,106
Current portion of notes payable	1,020,223	1,068,414
Current portion of revenue interest liability	2,342,251	2,162,160
Total current liabilities	23,964,717	35,857,873
Long-term portion of notes payable	726,361	1,146,956
Other long-term liabilities	447,249	549,023
Non current portion of revenue interest liability	12,362,381	12,913,519
Long-term convertible notes payable principal amount, plus accrued interest less unamortized debt discount of \$27,972 and \$55,944 as of June 30, 2006 and December 31, 2005, respectively	8,890,624	8,767,798
<b>Mandatorily Redeemable Convertible Preferred Stock:</b>		
Series E convertible preferred stock \$0.001 par value. Authorized 7,472,612 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 7,472,612 at June 30, 2006 and December 31, 2005, respectively (Redemption and liquidation value of \$0 as of June 30, 2006)		10,331,648

See accompanying Unaudited Notes to the Consolidated Financial Statements

**ACORDA THERAPEUTICS, INC. AND SUBSIDIARY****Consolidated Balance Sheets (Continued)**

	<b>June 30, 2006 (unaudited)</b>	<b>December 31, 2005</b>
Series I convertible preferred stock \$0.001 par value. Authorized 10,204,047 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 10,204,047 at June 30, 2006 and December 31, 2005, respectively (Redemption and liquidation value of \$0 as of June 30, 2006)		20,369,508
Series J convertible preferred stock \$0.001 par value. Authorized 112,790,233 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 112,790,233 at June 30, 2006 and December 31, 2005, respectively (Redemption and liquidation value of \$0 as of June 30, 2006)		47,355,590
Series K convertible preferred stock \$0.001 par value. Authorized 1,573,330 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 1,533,327 shares at June 30, 2006 and December 31, 2005, respectively (Redemption and liquidation value of \$0 at June 30, 2006)		13,155,593
Commitments and contingencies		
Stockholders' (deficit):		
Series A convertible preferred stock, \$0.001 par value. Authorized 1,646,068 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 1,306,068 shares at June 30, 2006 and December 31, 2005, respectively (liquidation value of \$0 as of June 30, 2006)		1,306
Series B convertible preferred stock, \$0.001 par value. Authorized 2,250,000 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 900,000 shares at June 30, 2006 and December 31, 2005, respectively (liquidation value of \$0 as of June 30, 2006)		900
Series C convertible preferred stock, \$0.001 par value. Authorized 333,333 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 333,333 at June 30, 2006 and December 31, 2005, respectively (liquidation value of \$0 as of June 30, 2006)		333
Series D convertible preferred stock, \$0.001 par value. Authorized 400,000 shares at June 30, 2006 and December 31, 2005; issued and outstanding none		
Series F convertible preferred stock, \$0.001 par value. Authorized 2,300,000 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 2,300,000 at June 30, 2006 and December 31, 2005, respectively (liquidation value of \$0 as of June 30, 2006)		2,300
Series G convertible preferred stock, \$0.001 par value. Authorized 1,250,000 shares at June 30, 2006 and December 31, 2005; issued and outstanding none		
Series H convertible preferred stock, \$0.001 par value. Authorized 1,575,229 shares at June 30, 2006 and December 31, 2005; issued and outstanding 0 and 1,575,229 shares at June 30, 2006 and December 31, 2005, respectively (liquidation value of \$0 as of June 30, 2006)		1,575

See accompanying Unaudited Notes to the Consolidated Financial Statements



**ACORDA THERAPEUTICS, INC. AND SUBSIDIARY****Consolidated Balance Sheets (Continued)**

	<b>June 30, 2006 (unaudited)</b>	<b>December 31, 2005</b>
Common stock, \$0.001 par value. Authorized 260,000,000 and 200,000,000 shares at June 30, 2006 and December 31, 2005, respectively; issued and outstanding 19,630,636 and 208,732 shares as of June 30, 2006 and December 31, 2005, respectively	19,631	209
Additional paid-in capital	215,666,654	91,501,190
Accumulated deficit	(217,882,066 )	(208,041,931 )
Other comprehensive (loss)	(2,852 )	(1,560 )
Total stockholders' (deficit)	(2,198,633 )	(116,535,678 )
Total liabilities, mandatorily redeemable convertible preferred stock and stockholders' (deficit)	\$ 44,192,699	\$ 33,911,830

See accompanying Unaudited Notes to the Consolidated Financial Statements



**ACORDA THERAPEUTICS, INC. AND SUBSIDIARY**  
**Consolidated Statements of Operations**  
**(unaudited)**

	Three-month period ended June 30, 2006	Three-month period ended June 30, 2005	Six-month period ended June 30, 2006	Six-month period ended June 30, 2005
Gross sales Zanaflex	\$ 7,892,453	\$ 477,859	\$ 11,766,038	\$ 478,183
Less: discounts and allowances	1,531,758	(704,570)	1,335,876	(844,436)
Net sales	9,424,211	(226,711)	13,101,914	(366,253)
Grant revenue	179,308	129,904	301,265	154,642
Total net revenue	9,603,519	(96,807)	13,403,179	(211,611)
Less: cost of sales	(1,343,906)	(1,086,004)	(2,385,124)	(1,567,144)
Gross profit	8,259,613	(1,182,811)	11,018,055	(1,778,755)
Operating expenses:				
Research and development	3,021,016	5,040,068	6,297,885	7,142,992
Sales and marketing	4,282,574	3,066,477	8,844,850	5,368,860
General and administrative	3,560,028	1,821,212	5,837,876	3,933,089
Total operating expenses	10,863,618	9,927,757	20,980,611	16,444,941
Operating loss	(2,604,005)	(11,110,568)	(9,962,556)	(18,223,696)
Other income (expense):				
Interest and amortization of debt discount expense	(603,643)	(370,768)	(907,534)	(519,979)
Interest income	310,807	147,638	572,878	257,939
Other income	488	1,028	2,852	1,028
Total other income (expense)	(292,348)	(222,102)	(331,804)	(261,012)
Cumulative effect of change in accounting principle			454,225	
Net loss	(2,896,353)	(11,332,670)	(9,840,135)	(18,484,708)
Beneficial conversion feature, accretion of issuance costs, preferred dividends, and fair value of warrants issued to convertible preferred stockholders		(5,997,359)	(36,007,456)	(12,209,506)
Net loss allocable to common stockholders	\$ (2,896,353)	\$ (17,330,029)	\$ (45,847,591)	\$ (30,694,214)
Net loss per share allocable to common stockholders basic and diluted	\$ (0.15)	\$ (85.88)	\$ (3.00)	\$ (152.78)
Weighted average common shares outstanding used in computing net loss per share allocable to common stockholders basic and diluted	19,628,928	201,782	15,278,187	200,903

See accompanying Unaudited Notes to the Consolidated Financial Statements.

**ACORDA THERAPEUTICS, INC. AND SUBSIDIARY**  
**Consolidated Statements of Cash Flows**  
**(unaudited)**

	Six-month period ended June 30, 2006	Six-month period ended June 30, 2005
Cash flows from operating activities:		
Net loss	\$ (9,840,135 )	\$ (18,484,708 )
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation expense	1,944,127	1,974,434
Amortization of note discount	23,310	65,621
Amortization of discount on short-term investments	7,783	
Cumulative effect of change in accounting principle	(454,225 )	
Accretion of discount	22,960	49,305
Unrealized gain on warrants	(51,774 )	
Depreciation and amortization expense	854,801	691,022
Changes in assets and liabilities:		
Increase in accounts receivable	(606,681 )	(2,207,838 )
Decrease (increase) in grant receivables	(68,697 )	63,182
Decrease (increase) in prepaid expenses and other current assets	815,503	(141,893 )
Increase in inventory held by the Company	(657,825 )	(2,824,878 )
Decrease (increase) in inventory held by others	64,127	(949,984 )
Decrease in other assets	4,240	
Increase (decrease) in accounts payable, accrued expenses, other current liabilities	(7,063,314 )	2,272,607
Decrease in returns liability	(1,831,211 )	(1,661,154 )
Increase (decrease) in deferred product revenue tablets	604,426	(1,282,019 )
Increase (decrease) in deferred product revenue capsules	(3,028,718 )	11,027,470
Decrease in royalty payable		(750,000 )
Restricted cash	(4,437 )	(2,660 )
Net cash used in operating activities	(19,265,740 )	(12,161,493 )
Cash flows from investing activities:		
Purchases of property and equipment	(259,871 )	(118,602 )
Purchases of short-term investments	(5,494,034 )	(11,367,539 )
Proceeds from maturities of short-term investments	6,986,000	9,330,000
Net cash (used in)/provided by investing activities	1,232,095	(2,156,141 )
Cash flows from financing activities:		
Proceeds from issuance of common stock	31,476,230	20,448
Proceeds from issuance of notes payable		5,785,215
Proceeds from issuance of warrants		214,785
Repayments of revenue interest liability	(1,027,770 )	
Repayments of notes payable	(491,745 )	(172,823 )
Net cash provided by financing activities	29,956,715	5,847,625
Net increase (decrease) in cash and cash equivalents	11,923,069	(8,470,009 )
Cash and cash equivalents at beginning of period	11,761,299	11,729,112
Cash and cash equivalents at end of period	\$ 23,684,368	\$ 3,259,103
Supplemental disclosure:		
Cash paid for interest	\$ 69,062	\$ 220,145
Non-cash charges related to convertible preferred stock:		
Beneficial conversion feature	48,470,740	9,699,463
Accretion of issuance costs	270,725	54,146
Preferred dividend	(12,734,009 )	2,670,682
Non-cash activities:		
Gain on put/call liability	50,000	

See accompanying Unaudited Notes to the Consolidated Financial Statements.

**ACORDA THERAPEUTICS, INC. AND SUBSIDIARY**

**Notes to Consolidated Financial Statements**

**(unaudited)**

**(1) Organization and Business Activities**

Acorda Therapeutics, Inc. (Acorda or the Company) is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.

The management of the Company is responsible for the accompanying unaudited interim consolidated financial statements and the related information included in the notes to the consolidated financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, including normal recurring adjustments necessary for the fair presentation of the Company's financial position and results of operations and cash flows for the periods presented. Results of operations for interim periods are not necessarily indicative of the results to be expected for the entire year.

These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2005 included in the Company's Annual Report on Form 10-K for such year, as filed with the Securities and Exchange Commission (the SEC). We have made certain reclassifications to the 2005 financial statements to conform to the 2006 presentation.

The Company completed an initial public offering on February 9, 2006. As part of that offering, 6,075,614 shares of the Company's common stock were sold, resulting in net proceeds of approximately \$31.5 million after deducting the underwriting discount and offering expenses payable by the Company.

Upon the closing of the initial public offering, all of the Company's convertible preferred stock and mandatorily redeemable convertible preferred stock was converted into 13,338,278 shares of common stock. This conversion resulting in the following: (a) recognition of the unamortized portion of a beneficial conversion charge of \$48.5 million; (b) recognition of the unamortized portion of issuance costs relating to Series E, Series I, Series J and Series K preferred stock of \$271,000; and (c) net reversal of accrued preferred dividends on Series J and Series K preferred stock of \$12.7 million (see Note 4 to the consolidated financial statements).

On September 18, 2005, the Company's Board of Directors approved a 1-for-1.3 reverse stock split, which became effective on January 11, 2006. All references to common stock, common shares outstanding, average number of common shares outstanding, per share amounts, options and warrants and notes payable in these financial statements and notes to financial statements have been restated to reflect the 1-for-1.3 common stock reverse split on a retroactive basis.

The Company is devoting substantially all of its efforts to promoting sales of Zanaflex Capsules, conducting clinical trials, pursuing regulatory approval for products under development, and engaging in preclinical development. The Company has begun to generate product revenues but has not achieved profitable operations or positive cash flows from operations. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. The Company's accumulated deficit since inception through June 30, 2006 was \$217.9 million and the Company expects to continue to incur losses for the foreseeable future. Further, the Company's future operations are dependent on the success of the Company in commercializing Zanaflex Capsules, completing the clinical development of Fampridine-SR in MS and obtaining regulatory approval and market acceptance of this product candidate and advancing its preclinical programs.

The Company finances its operations through a combination of issuance of equity securities, revenues from Zanaflex Capsules, loans and, to a lesser extent, grants. There are no assurances that the Company

will be successful in obtaining an adequate level of financing needed to fund its development and commercialization efforts. The Company believes that its current financial resources and sources of liquidity should be adequate to fund operations to July 1, 2007 based on the Company's current projected revenue and spending levels. To the extent our capital resources are insufficient to meet future operating requirements, we will need to raise additional capital or incur indebtedness to fund our operations. We may be unable to obtain additional debt or equity financing on acceptable terms, if at all. If adequate funds are not available, we may be required to curtail our sales and marketing efforts, delay, reduce the scope of or eliminate some of our research and development programs or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.

## **(2) Summary of Significant Accounting Policies**

### ***Principles of Consolidation***

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America and include the results of operations of the Company and its majority owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

### ***Use of Estimates***

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include research and development (clinical trial accrual), beneficial conversion charges, stock warrants and option accounting, which are all dependent on the fair value of the Company's equity security. In addition, the Company recognizes revenue based on estimated prescriptions filled. The Company adjusts its inventory value based on an estimate of inventory that may be returned. Actual results could differ from those estimates.

### ***Revenue Recognition***

The Company applies the revenue recognition guidance in SFAS No. 48, *Revenue Recognition When the Right of Return Exists*, which amongst other criteria requires that future returns can be reasonably estimated in order to recognize revenue. The amount of future tablet returns is uncertain due to generic competition and customer conversion to Zanaflex Capsules. Zanaflex Capsules are a new product with no historical return data. Due to the uncertainty of returns for both products, the Company is accounting for these product shipments using a deferred revenue recognition model. Under the deferred revenue model, the Company does not recognize revenue upon product shipment. For these product shipments, the Company invoices the wholesaler, records deferred revenue at gross invoice sales price, and classifies the cost basis of the product held by the wholesaler as a component of inventory. The Company recognizes revenue when prescribed to the end-user, on a first-in first-out (FIFO) basis. The Company's revenue to be recognized is based on (1) the estimated prescription demand based on pharmacy sales for its products, and (2) the Company's analysis of third-party information, including third-party market research data. The Company's estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information is itself in the form of estimates, and reflect other limitations. The Company's sales and revenue recognition reflects the Company's estimates of actual product prescribed to the end-user.

The Company's net revenues represent total revenues less allowances for customer credits, including estimated discounts, rebates, and chargebacks. Product shipping and handling costs are included in cost of sales. These reserves are recorded in accordance with Emerging Issues Task Force (EITF) Issue No. 01-9,

*Accounting for Consideration Given by a Vendor to a Customer*, which states that cash consideration given by a vendor to a customer is presumed to be a reduction of the selling prices of the vendor's products or services and, therefore, should be characterized as a reduction of revenue when recognized in the vendor's income statement. At the time product is shipped to wholesalers, an adjustment is recorded for estimated chargebacks, rebates, and discounts. These reserves are established by management as its best estimate based on available information and is adjusted to reflect known changes in the factors that impact such reserves. Reserves for chargebacks, rebates and discounts are established based on the contractual terms with customers, analysis of historical levels of discounts, chargebacks and rebates, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for each product and anticipated introduction of competitive products. In addition, the Company records a charge to cost of goods sold for the cost basis of the estimated product returns the Company believes may ultimately be realized at the time of product shipment to wholesalers. The Company has recognized this charge at the date of shipment since it is probable that it will receive a level of returned products; upon the return of such product it will be unable to resell the product considering its expiration dating; and it can reasonably estimate a range of returns. This charge represents the cost basis for the low end of the range of the Company's estimated returns.

#### ***Concentration of Risk***

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of investments in cash and cash equivalents, restricted cash, accounts receivable and debt securities. The Company maintains cash and cash equivalents, restricted cash and debt securities with approved financial institutions. The Company is exposed to credit risks in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.

The Company is substantially dependent upon Elan for several activities related to the development and commercialization of Fampridine-SR. The Company will rely on Elan to complete the chemistry, manufacturing and controls section of the New Drug Application (NDA) for Fampridine-SR in multiple sclerosis. If Elan fails to provide these parts of the NDA in a complete and timely manner the Company could incur delays in filing of its NDA for Fampridine-SR in multiple sclerosis.

The Company relies on a single manufacturer, Elan, for the supply of Zanaflex Capsules and through February 2007 on another single manufacturer, Novartis, for the supply of tizanidine, the active pharmaceutical ingredient, or API, in Zanaflex Capsules. If either Elan or Novartis experiences any disruption in their operations, a delay or interruption in the supply of the Company's products could result until the affected supplier cures the problem or the Company locates an alternative source of supply. The Company may not be able to enter into alternative supply arrangements on terms that are commercially favorable, if at all. Any new supplier would also be required to qualify under applicable regulatory requirements. The Company could experience substantial delays before it is able to qualify any new supplier and transfer the required manufacturing technology to that supplier. Novartis has discontinued production of tizanidine and successfully transferred the methods of manufacturing tizanidine to Rohner, an API manufacturer in Pratteln, Switzerland. The Company verified this transfer and visited Rohner's manufacturing site in February 2006, following the commencement of Rohner's manufacture of tizanidine. The Company has also identified an alternate source for tizanidine in collaboration with Elan. However, the Company does not have an agreement with an alternative tizanidine manufacturer, and does not anticipate entering into a supply agreement for API with Elan or Rohner. It is the responsibility of each of Novartis and Elan to procure the API required to meet their contractual obligations under their respective supply agreements with the Company. The Company does not anticipate an interruption in API supply, and any cost associated with validating API suppliers would be incurred by Novartis or Elan. The Company has arranged with another company, Sharp Corporation, to bottle and package Zanaflex tablets.

The Company has agreed to purchase at least 75% of its Fampridine-SR product requirements from Elan, and must make compensatory payments if it does not purchase 100% of its requirements from Elan. The Company and Elan have agreed that the Company may purchase up to 25% of its annual Fampridine-SR requirements from Patheon, Inc., a qualified manufacturing source of Fampridine-SR, provided that the Company makes compensatory payments to Elan. In addition, the Company does not have direct contractual relationships with the suppliers of fampridine, the active pharmaceutical ingredient in Fampridine-SR, referred to as API. Currently, the Company is relying on Elan's contracts with third parties to supply API. If Elan or an alternative manufacturer is unable to obtain API from these suppliers for any reason, a new supplier would have to be identified by the Company. Although other potential sources of API are available, any new supplier would be required to qualify under applicable regulatory requirements. Any delays in obtaining API to manufacture Fampridine-SR could delay the clinical trials of Fampridine-SR.

### **Earnings per Share**

Net loss per share is computed in accordance with SFAS No. 128, *Earnings Per Share*, by dividing the net loss allocable to common stockholders by the weighted average number of shares of common stock outstanding. For the three and six-month periods ended June 30, 2006 and June 30, 2005 all of the Company's common share equivalents would have been anti-dilutive and have not been used in the calculation of diluted net loss per share. As such, the numerator and the denominator used in computing both basic and diluted net loss per share allocable to common stockholders for each year are equal. The Company has reflected the beneficial conversion feature for Series E, Series I and Series J, accretion of issuance costs for Series E, Series I, Series J and Series K, and preferred dividend for Series J and Series K in the net loss allocable to common stockholders as set forth below.

	<b>Beneficial conversion feature</b>	<b>Accretion of issuance costs</b>	<b>Preferred dividend</b>
For the three-month period ended June 30, 2006	\$	\$	\$
For the three-month period ended June 30, 2005	4,849,732	27,073	1,335,339
For the six-month period ended June 30, 2006	48,470,740	270,725	(12,734,009)
For the six-month period ended June 30, 2005	9,699,463	54,146	2,670,682

### **Stock-Based Compensation**

The Company has various stock-based employee and non-employee compensation plans, which are described more fully in Note 5.

Historically, the Company accounted for share-based compensation costs under the provisions of Statement of Financial Accounting Standards 123 (SFAS No. 123), *Accounting for Stock-Based Compensation*, using a fair-value-based method of accounting for stock-based employee compensation plans.

On January 1, 2006, the Company adopted the provisions of Statement of Financial Accounting Standards 123 (revised 2004), *Share-Based Payment* (SFAS No. 123R), which requires that the costs resulting from all share-based payment transactions be recognized in the financial statements at their fair values. The Company adopted SFAS No. 123R using the modified prospective application method under which the provisions of SFAS No. 123R apply to new awards and to awards modified, repurchased, or cancelled after the adoption date. Additionally, compensation cost for the portion of the awards for which the requisite service has not been rendered that are outstanding as of the adoption date is recognized in the Consolidated Statement of Operations over the remaining service period after the adoption date based on the award's original estimate of fair value. Results for prior periods have not been restated.

In connection with the adoption of SFAS No. 123R, the Company changed from recognizing the effect of forfeitures as they occur to estimating the number of outstanding instruments for which the requisite service is not expected to be rendered. Prior to the adoption of SFAS No. 123R, the Company

recognized forfeitures associated with its share-based awards as they occurred rather than estimating forfeitures. Upon adoption of SFAS No. 123R, the Company recorded a cumulative effect of change in accounting principle of \$454,225, calculated as the difference between compensation cost recognized through December 31, 2005 using actual forfeitures and the cost that would have been recognized to date using estimated forfeitures. The Company estimates that its future annual forfeiture rate will be approximately 5%.

The Company accounts for stock options granted to non-employees on a fair-value basis in accordance with EITF No. 96-18, *Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services*, and FASB Interpretation No. 28, *Accounting for Stock Appreciation Rights and Other Variable Stock Option or Award Plans an Interpretation of APB Opinion No. 15 and 25*.

### **(3) Beneficial Conversion Feature**

In May 2003, the Company completed a private placement of 112,790,233 shares of Series J mandatorily redeemable convertible preferred stock at \$0.49 per share for an aggregate purchase price of approximately \$55,267,000.

As part of this financing, the original conversion price of the Series A through Series I preferred stock was reduced as a result of anti-dilution adjustments, which resulted in a beneficial conversion amounting to \$80,730,286 in accordance with EITF No. 98-5, *Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios* and EITF No. 00-27, *Application of Issue No. 98-5 to Certain Convertible Instruments*. The beneficial conversion charge of \$20,860,491 relating to Series A, Series B, Series C, Series F and Series H convertible preferred stock, which were not mandatorily redeemable and could be converted at any time at the option of the holders to common stock, was recorded as an immediate charge to additional paid-in capital. The remaining beneficial conversion amount of \$59,869,795 related to Series E and Series I convertible preferred stock, which were mandatorily redeemable at any time on or after June 30, 2008, was being accreted ratably over the mandatory redemption period. Such accretion amounted to \$29,058,676 and \$5,814,922 for the six-month periods ended June 30, 2006 and 2005, respectively, and is charged to additional paid-in capital. Upon completion of the company's initial public offering on February 9, 2006, the remaining beneficial conversion amount was fully accreted.

In addition, the issuance of Series J mandatorily redeemable convertible preferred stock resulted in a beneficial conversion amounting to \$39,994,812 in accordance with EITF No. 98-5. The beneficial conversion is calculated based on the estimated fair value of the Company's common stock price per share at the date of issuance of Series J preferred stock of approximately \$10.14 per share of common stock, which was calculated based on the estimated projected midpoint of the range of the Company's initial public offering price per common share, which was planned in the fourth calendar quarter of 2003, and the stock price appreciation in comparable public companies from May 2003 to August 2003. The beneficial conversion feature was being accreted ratably over the mandatory redemption period, with a charge to additional paid-in capital of \$19,412,064 and \$3,884,541 for the six-month periods ended June 30, 2006 and 2005, respectively. Upon completion of the Company's initial public offering on February 9, 2006, the remaining beneficial conversion amount was fully accreted.

### **(4) Mandatorily Redeemable Convertible Preferred Stock and Convertible Preferred Stock**

The board of directors of the Company had authorized 141,754,865 shares of convertible preferred stock, designated as Series A, B, C, D, E, F, G, H, I, J and K preferred stock (Series A, Series B, Series C, Series D, Series E, Series F, Series G, Series H, Series I, Series J and Series K; collectively, the Preferred Stock). Series E, Series I, Series J and Series K are mandatorily redeemable convertible preferred stock (Redeemable Preferred Stock). Upon the Company's initial public offering in February 2006, all the Company's outstanding Preferred Stock was converted into common stock.

The terms of the Preferred Stock were as follows:

**(a) Dividends**

The Preferred Stock (except Series J and Series K) were entitled to noncumulative dividends prior to and in preference to dividends declared or paid on the common stock, at the rate of \$0.10 per share per annum for Series A through Series H and at the rate of \$0.39 per share per annum for Series I when and if declared by the board of directors. Dividends on Series J and Series K were cumulative and accrued on each share of Series J Preferred Stock and Series K Preferred Stock commencing on the date of issuance, whether or not earned or declared at the rate of \$0.0392 per share per annum for Series J and at the rate of \$0.60 per share per annum for Series K, based on the original issue price of Series J Preferred Stock and Series K Preferred Stock, prior and in preference to any declaration or payment of any dividend on any other Series of Preferred Stock holders (Series A through Series I). Accrued dividends for Series J and K were \$11.1 million and \$1.7 million as of December 31, 2005. Upon the Company's initial public offering in February 2006, the total dividend accruals of \$11.6 million and \$1.8 million for Series J and K, respectively, were reversed. The net reversal of dividends for the six-month period ended June 30, 2006 was \$12.7 million, including accruals made from the beginning of the year up to the initial public offering.

**(b) Conversion**

The Preferred Stock automatically converted into common stock upon the completion of the Company's initial public offering on February 9, 2006.

Preferred stock	Shares outstanding at February 9, 2006	Conversion Price	Shares of Common Stock
Series A	1,306,068	\$ 9.06	144,074
Series B	900,000	11.86	151,820
Series C	333,333	14.64	68,339
Series D		11.86	
Series E	7,472,612	13.81	1,461,363
Series F	2,300,000	13.81	449,803
Series G		(1 )	
Series H	1,575,229	15.34	333,827
Series I	10,204,047	17.11	2,319,457
Series J	112,790,233	7.64	7,230,118
Series K	1,533,327	9.75	1,179,478

(1) The product of (x) the number of Series G Preferred Stock surrendered and (y) the number determined by dividing (i) the greater of \$31.20 or 80% of the closing price per share of the most recently completed bona fide equity financing of the Company prior to the issuance of Series G Preferred Stock by (ii) the Series G conversion price in effect.

**(5) Common Stock Options, Warrants and Restricted Stock**

On June 18, 1999, the Company's board of directors approved the adoption of the Acorda Therapeutics, Inc. 1999 Employee Stock Option Plan (the 1999 Plan). All employees of the Company were eligible to participate in the 1999 Plan, including executive officers, as well as directors, independent contractors, and agents of the Company. The 1999 Plan also covers the issuance of restricted stock. The 1999 Plan is administered by the Compensation Committee of the Board of Directors, which selects the individuals to be granted options and stock appreciation rights, determines the time or times at which options and stock appreciation rights shall be granted under the 1999 Plan, determines the number of shares to be granted subject to any option or stock appreciation right under the 1999 Plan and the duration of each option and stock appreciation right, and makes any other determinations necessary, advisable, and/or appropriate to administer the 1999 Plan. Under the 1999 Plan, each option granted expires no later than the tenth anniversary of the date of its grant. Compensation expense is calculated using a



Black-Scholes calculation with the expense being recognized over the vesting period. No option may be granted pursuant to the 1999 Plan more than ten years after the date on which the 1999 Plan was adopted by the board of directors and any option granted under the 1999 Plan shall, by its terms, not be exercisable more than ten years after the date of grant. The number of shares authorized for issuance under the 1999 Plan is 3,186,856.

On January 12, 2006, the Company's board of directors approved the adoption of the Acorda Therapeutics, Inc. 2006 Employee Incentive Plan (the 2006 Plan). This 2006 Plan shall serve as the successor to the Company's 1999 Plan, as amended, and no further option grants or stock issuances shall be made under the 1999 Plan after the effective date, as determined under Section 14 of the 2006 Plan. All employees of the Company are eligible to participate in the 2006 Plan, including executive officers, as well as directors, independent contractors, and agents of the Company. The 2006 Plan also covers the issuance of restricted stock. The 2006 Plan is administered by the Compensation Committee of the board of directors, which selects the individuals to be granted options and stock appreciation rights, determines the time or times at which options and stock appreciation rights shall be granted under the 2006 Plan, determines the number of shares to be granted subject to any option or stock appreciation right under the 2006 Plan and the duration of each option and stock appreciation right, and makes any other determinations necessary, advisable, and/or appropriate to administer the 2006 Plan. Under the 2006 Plan, each option granted expires no later than the tenth anniversary of the date of its grant. Compensation expense is calculated using a Black-Scholes calculation with the expense being recognized over the vesting period. No option may be granted pursuant to the 2006 Plan more than ten years after the date on which the 2006 Plan was adopted by the board of directors and any option granted under the 2006 Plan shall, by its terms, not be exercisable more than ten years after the date of grant. Subject to increase under Section 3(b) of the 2006 Plan and adjustment under Section 10 of the 2006 Plan, the number of shares of common stock reserved for issuance pursuant to awards made under the 2006 Plan shall not exceed 3,000,000 shares of stock. The total number of shares of common stock available for issuance under this 2006 Plan, including shares of common stock subject to the then outstanding awards, shall automatically increase on January 1 of each year during the term of this plan, beginning 2007, by a number of shares of common stock equal to 4% of the outstanding shares of common stock on that date, unless otherwise determined by the Board of Directors. Upon the exercise of options in the future, the Company intends to issue new shares.

The effects of applying SFAS No. 123R in a particular year, may not be representative of the effects on reported net income or loss for future years. The fair value of each option granted is estimated on the date of grant using an option-pricing model with the following weighted average assumptions:

	Three-month period ended June 30		Six-month period ended June 30,	
	2006	2005	2006	2005
Employees and directors:				
Estimated volatility	69.6 %	80.0 %	72.4 %	82.8 %
Expected life in years	5.4	5.0	5.4	5.0
Risk free interest rate	5.1 %	3.7 %	4.6 %	3.7 %
Dividend yield				

The Company estimated volatility for purposes of computing compensation expense on its employee and non-employee options using the volatility of public companies that the Company considered comparable. The expected life used to estimate the fair value of non-employee options is equal to the contractual life of the option granted, which is 10 years. The expected life used to estimate the fair value of employee options is 5.4 years. The Company based this assumption on the 50th percentile of 10 peer companies' choices for expected life for their valuations.

The weighted average fair value per share of options granted to employees and directors for the three-month periods ended June 30, 2006 and 2005 amounted to approximately \$2.65 and \$4.14 respectively. The

weighted average fair value per share of options granted to employees and directors for the six-month periods ended June 30, 2006 and 2005 amounted to approximately \$3.78 and \$5.06 respectively. No options were granted to non-employees for the six-month periods ended June 30, 2006 and 2005.

During the three-month period ended June 30, 2006, the Company granted 53,761 stock options to employees under the 2006 Plan. During the six-month period ended June 30, 2006, the Company granted 783,740 stock options to employees and directors under the 2006 Plan. The stock options were issued with a weighted average exercise price of \$6.00 per share. 32,698 of these options will vest over a three-year vesting schedule, and 751,042 will vest over a four-year vesting schedule. As a result of these grants the total compensation charge is \$2,622,382, of which \$256,285 was recognized during the six-month period ended June 30, 2006.

Compensation costs for options and restricted stock granted to employees and directors amounted to \$913,820 and \$710,091 for the three-month periods ended June 30, 2006 and 2005, respectively. Compensation costs for options and restricted stock granted to employees and directors amounted to \$1,943,246 and \$1,974,262 for the six-month periods ended June 30, 2006 and 2005, respectively. There were no compensation costs capitalized in our inventory balances. Compensation expense for options and restricted stock granted to employees and directors are classified between research and development, sales and marketing and general and administrative expense based on employee job function. Compensation costs recognized during the six-month period ended June 30, 2006 was \$223,803 less than had the Company not adopted SFAS No. 123R and it continued to apply the fair value provisions of SFAS No. 123.

Options granted to non-employees vest immediately or over a one to four year period based upon future service requirements. Compensation cost for options granted to non-employees amounted to \$881 and \$172 for the six-month periods ended June 30, 2006 and 2005, respectively. The amount of compensation cost to be recorded in the future for options granted to non-employees is subject to change each reporting period based upon changes in the estimated fair value of the Company's common stock, estimated volatility and risk free interest rate until the non-employee completed performance under the option agreement.

A summary of stock option activity for the six-month period ended June 30, 2006 is presented below:

#### *Stock Option and Warrant Activity*

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Intrinsic Value
Balance at January 1, 2006	1,770,494	\$ 3.44		
Granted	783,740	6.00		
Forfeited	(22,199 )	5.64		
Exercised	(10,575 )	1.81		
Balance at June 30, 2006	2,521,460	\$ 4.22	8.2	\$ 1,629,084
Vested and expected to vest at June 30, 2006	2,391,686	\$4.85	8.1	\$ 1,617,275
Vested and exercisable at June 30, 2006	1,315,879	\$ 3.67	7.1	\$ 1,611,050

Nonvested stock options	Number of Shares	Weighted Average Grant Date Fair Value
Nonvested at January 1, 2006	556,460	\$ 10.91
Granted	783,740	6.00
Vested	(122,022 )	14.21
Forfeited	(12,597 )	8.13
Nonvested at June 30, 2006	1,205,581	\$ 7.41

Range of exercise price	Options and Warrants Outstanding			Options and Warrants Exercisable	
	Outstanding as of June 30, 2006	Weighted- average remaining contractual life	Weighted- average exercise price	Exercisable as of June 30, 2006	Weighted- average exercise price
\$0.16-\$3.12	1,120,043	6.90	\$ 2.65	1,060,813	\$ 2.58
\$5.85-\$12.48	1,397,347	9.16	7.16	250,996	7.97
\$23.40	4,070	5.19	23.40	4,070	23.40
	2,521,460	8.15	\$ 5.18	1,315,879	\$ 3.67

Unrecognized compensation costs for unvested awards as of June 30, 2006 totaled \$5.7 million and is expected to be recognized over a weighted average period of approximately 4.0 years.

The Company had 755,103 shares of restricted stock outstanding with a weighted average grant date fair value of \$6.81 as of January 1, 2006. No additional shares were granted during the six-month period ended June 30, 2006. No shares have been vested, forfeited or exercised during the period.

## (6) Product Returns

As part of the terms of the Zanaflex asset purchase agreement, any product returned within six months of acquisition date was the obligation of Elan. Beginning in January 2005, such returns became a liability of the Company. Through June 30, 2006, the Company accepted \$4.7 million in total product returns, of which \$2.3 million was for product not sold by the Company. The Company accepts product returned up to twelve months subsequent to its expiration date. The Company recorded a charge to discounts and allowances of \$4.1 million in the year ending December 31, 2004 to record an estimated liability for returns of Zanaflex tablets sold by Elan. The Company continued to receive returns of the product sold by Elan through June 2006 at which point the right of return expired and the remaining \$1.8 million accrual balance was reversed through discounts and allowances.

As part of the Zanaflex acquisition, the Company purchased certain tablet inventory from Elan that expired within one year. The majority of this product was sold by the Company during July 2004 through March 2005. The Company received returns of the product sold by Elan through June 2006 at which point the right of return expired and the company recognized the \$2.2 million deferred revenue balance as gross sales.

## (7) Income Taxes

The Company had available net operating loss carryforwards (NOL) of approximately \$143.9 million and \$130.0 million as of June 30, 2006 and December 31, 2005 respectively, for federal and state income tax purposes, which are available to offset future federal and state taxable income, if any, and expire between 2010 and 2025. The Company also has research and development tax credit carryforwards of approximately \$1.2 million and \$1.2 million as of June 30, 2006 and December 31, 2005, respectively, for federal income tax reporting purposes that are available to reduce federal income taxes, if any, and expire in future years beginning in 2018.

At June 30, 2006 and December 31, 2005, the Company had a deferred tax asset of \$88.5 million and \$84.4 million, respectively, offset by a full valuation allowance. Since inception, the Company has incurred substantial losses and expects to incur substantial losses in future periods. The Tax Reform Act of 1986 (the "Act") provides for a limitation of the annual use of NOL and research and development tax credit carryforwards (following certain ownership changes, as defined by the Act) that could significantly limit the Company's ability to utilize these carryforwards. The Company has experienced various ownership changes, as a result of past financings and its initial public offering in February 2006. Accordingly, the Company's ability to utilize the aforementioned carryforwards may be limited. Additionally, because U.S. tax laws limit the time during which these carryforwards may be applied against future taxes, the Company may not be able to take full advantage of these attributes for federal income tax purposes. Because of the above mentioned factors, the Company has not recognized its net deferred tax assets as of and for all periods presented. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets and no tax benefit has been recognized relative to its pretax losses.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

The following discussion and analysis of our consolidated financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q.

**Background**

Since we commenced operations in 1995, we have devoted substantially all of our resources to the identification, development and commercialization of novel therapies that improve neurological function in people with Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and other disorders of the CNS. Our marketed drug, Zanaflex Capsules, is FDA-approved for the management of spasticity. Our lead product candidate, Fampridine-SR, is in a Phase 3 clinical trial for the improvement of walking ability in people with MS. Our preclinical programs also target MS and SCI, as well as other CNS disorders, including stroke and traumatic brain injury.

From 1995 until mid-2004, we were engaged almost exclusively in the in-licensing of compounds and the preclinical and clinical development of these compounds. We licensed the rights to Fampridine-SR from Elan for the treatment of SCI in 1997. In September 2003 we entered into an amended license agreement with Elan that granted us exclusive worldwide rights to Fampridine-SR in return for the payment of royalties and milestones. In addition, we entered into a supply agreement under which Elan provides Fampridine-SR based upon an agreed upon price schedule.

In September 2003, we entered into a collaboration agreement with Teva to jointly develop and promote in the United States products containing valroceamide, pursuant to which we made an initial payment to Teva of \$2.0 million. We and Teva amicably terminated this collaboration agreement in June 2005 and in connection with the termination we paid Teva approximately \$3.1 million. We and Teva have no further obligations to each other under this collaboration agreement.

We have expended a significant portion of our funds on a number of clinical trials for Fampridine-SR, our most advanced product candidate, including two Phase 3 clinical trials of Fampridine-SR in SCI and a Phase 2 clinical trial in MS, the results of which were announced in March 2004. An earlier Phase 2 clinical trial in MS was completed in 2001. In mid-2004, we decided to put our clinical trials of Fampridine-SR in SCI on hold, and refocused our efforts on our ongoing Fampridine-SR in MS program, leading to our current Phase 3 clinical trial of Fampridine-SR for improvement of walking ability in people with MS. We may resume our clinical development of Fampridine-SR for SCI following completion of our MS clinical program, or sooner.

In July 2004, we acquired all of Elan's research, development, distribution, sales and marketing rights to Zanaflex Capsules and Zanaflex tablets in the United States. These products are FDA-approved for the management of spasticity. We made an upfront payment to Elan of \$2.0 million and are obligated to pay royalties on sales and to make milestone payments upon achievement of specified sales levels. To date, we have achieved two milestones, the first triggering payment of \$1.5 million, 50% of which was paid in the first quarter of 2005 and 50% of which was paid in the first quarter of 2006, and the second payment of \$3.0 million in the first quarter of 2006. We expect to reach the third milestone level in the fourth quarter 2006 which would trigger a \$5.0 million payment that would be payable in the first quarter 2007. There are additional future milestones that could result in payments by us to Elan of \$10.0 million. As part of our Zanaflex acquisition, we entered into a long-term supply agreement with Elan under which Elan provides us with Zanaflex Capsules. Elan also assigned us its rights under an agreement with Novartis for the supply of tizanidine and Zanaflex tablets.

Our marketing efforts are focused on Zanaflex Capsules, which we launched in April 2005. Zanaflex tablets lost compound patent protection in 2002 and both Zanaflex Capsules and Zanaflex tablets compete with 12 generic tizanidine products. Although we currently distribute Zanaflex tablets, we do not, and do not intend to, actively promote Zanaflex tablets. As a result, prescriptions for Zanaflex tablets have

declined and we expect that they will continue to decline. Our goal is to convert as many sales of Zanaflex tablets and generic tizanidine tablets to sales of Zanaflex Capsules as possible. We believe that sales of Zanaflex Capsules will constitute a significant portion of our total revenue for the foreseeable future.

In late 2004, we began establishing our own specialist sales force in the United States, which consisted of 32 sales professionals as of June 30, 2006. This sales force has targeted neurologists and other prescribers who specialize in treating people with conditions that involve spasticity. Members of this sales force also call on managed care organizations, pharmacists and distribution customers. In August 2005, we entered into an agreement with Cardinal Health, under which it provided approximately 160 sales representatives to market Zanaflex Capsules, on a non-exclusive basis, to primary care physicians in the United States. Sales in the primary care market did not reach the targets specified in our agreement. We gave notice of termination of the agreement to Cardinal Health. We have agreed to make a payment to Cardinal Health in connection with that termination and have agreed on the other conditions of the termination. We are in the process of finalizing that agreement. We do not expect the final payment to be significant or impact our financial condition.

In May 2005 we retained Access Worldwide Communications (Access) to provide a small, dedicated sales force of pharmaceutical telesales professionals to contact primary care, specialty physicians and pharmacists. In February 2006 we expanded the scope of the arrangement with Access and transferred some of the primary care physician contacts previously covered by Cardinal Health to Access. In addition, we initiated a pilot program with Innovex Inc. that provides six part-time representatives making exclusive calls promoting Zanaflex Capsules to primary care physicians, focusing on some of the contacts previously covered by Cardinal Health. We will continue to evaluate the market opportunity for Zanaflex Capsules in the primary care market.

In December 2005, we entered into a revenue interests assignment agreement with Paul Royalty Fund (PRF) pursuant to which we assigned PRF the right to receive a portion of our net revenues (as defined in the agreement which definition is different from our net revenues as determined in accordance with generally accepted accounting principles) from Zanaflex Capsules, Zanaflex tablets and any future Zanaflex products. The agreement covers all such Zanaflex net revenues generated from October 1, 2005 through and including December 31, 2015, unless the agreement is terminated earlier. In consideration for the assignment, PRF paid us \$15.0 million at signing. We used approximately \$3.0 million of that payment to repay a portion of the amount we owe to GE Capital, \$200,000 of that payment for expenses associated with such repayment and \$500,000 of that payment to reimburse PRF for expenses it incurred in the transaction. Under our agreement with PRF, we are required to use the remainder of the amount we received at signing and any other amounts we receive under the agreement to support commercialization, sales, marketing, clinical and regulatory activities and other financial obligations related specifically and solely to our Zanaflex operations. If our Zanaflex net revenues in 2005 had equaled or exceeded \$11.0 million and our Zanaflex net revenues in the first six months of 2006 had equaled or exceeded \$16.0 million, at our election, PRF would also have been required to pay us an additional \$5.0 million. We did not meet this milestone. If our Zanaflex net revenues in 2006 equal or exceed \$33.5 million, at our discretion, PRF would be required to pay us an additional \$5 million. If we meet this milestone and decide to borrow these additional funds, we would be required to pay PRF \$5.0 million on December 1, 2010. For more information regarding our agreement with PRF, see [Liquidity and Capital Resources](#) [Financing Arrangements](#).

The Company completed an initial public offering on February 9, 2006. As part of that offering, 6,075,614 shares of the Company's common stock were sold, resulting in net proceeds of approximately \$31.5 million after deducting the underwriting discount and offering expenses payable by the Company.

Upon the closing of the initial public offering, all of the Company's convertible preferred stock and mandatorily redeemable convertible preferred stock was converted into 13,338,278 shares of common stock. This conversion resulted in the following: (a) recognition of the unamortized portion of a beneficial conversion charge of \$48.5 million; (b) recognition of the unamortized portion of issuance costs relating to

Series E, Series I, Series J and Series K preferred stock of \$271,000; and (c) reversal of accrued preferred dividends on Series J and Series K preferred stock of \$12.7 million.

## Results of Operations

### *Three-Month Period Ended June 30, 2006 Compared to June 30, 2005*

#### *Gross Sales*

We recognized revenue from the sale of Zanaflex Capsules and Zanaflex tablets of \$7.9 million for the three-month period ended June 30, 2006, as compared to \$478,000 for the three-month period ended June 30, 2005. We recognize product sales using a deferred revenue recognition model meaning that shipments to wholesalers are recorded as deferred revenue and only recognized as revenue when end-user prescriptions of the product are reported. During the three-month period ended June 30, 2006, we adopted IMS Health data as the prescription data source used as the basis for recognizing shipments of Zanaflex product as revenue. Included in gross sales for the three-month period ended June 30, 2006 is an additional \$621,000 resulting from the change in data vendors.

As part of the Zanaflex acquisition, the Company purchased certain tablet inventory from Elan that expired within one year. The majority of this product was sold by the Company during July 2004 through March 2005. The Company deferred revenue for this product due to the uncertainty of future returns. The Company received returns of the product sold by Elan through June 2006 at which point the right of return expired and the Company recognized the \$2.2 million deferred revenue balance as gross sales.

Gross sales in the three-month period ended June 30, 2005 consisted of Zanaflex tablet revenue recognized based on prescription data which we began receiving in March 2005, which is when we began receiving prescription data for tablets containing a code clearly identifying these prescriptions as having been filled with product we sold. We did not recognize revenue from Zanaflex Capsules prescription data until after our launch of the product in April 2005.

#### *Discounts and Allowances*

We recorded negative discounts and allowances of \$1.5 million for the three-month period ended June 30, 2006 as compared to \$705,000 for the three-month period ended June 30, 2005. As part of the Zanaflex acquisition in 2004, we agreed to accept returns of Zanaflex tablets that were returned subsequent to January 17, 2005, including returns of product that was originally sold by Elan. Product returns prior to that date were the responsibility of Elan. As a result of this agreement in December 2004 we recorded a return liability of \$4.1 million which was our best estimate of the Zanaflex tablet returns for which we could potentially become liable. Our obligation to continue to accept these returns ended in June 2006. As a result of the returns we accepted since 2004, the net balance remaining on this liability was approximately \$1.8 million. We reversed this liability in June 2006 which resulted in a reduction in discounts and allowances of \$1.8 million and a corresponding reduction of the product return liability on our balance sheet.

Discounts and allowances are recorded when Zanaflex Capsules and Zanaflex tablets are shipped to wholesalers. Discounts and allowances for the three-month period ended June 30, 2006 consisted of a negative \$1.8 million due to the Elan product return liability reversal described above, \$128,000 in cash discounts and \$141,000 in allowances for chargebacks and rebates. Discounts and allowances for the three-month period ended June 30, 2005, consisted of \$534,000 in cash discounts and allowances of \$171,000 for chargebacks and rebates.

### *Grant Revenue*

Grant revenue for the three-month period ended June 30, 2006 was \$179,000 compared to \$130,000 for the three-month period ended June 30, 2005. Grant revenue is recognized when the related research expenses are incurred and our performance obligations under the terms of the respective contract are satisfied.

### *Cost of Sales*

We recorded cost of sales of \$1.3 million for the three-month period ended June 30, 2006 as compared to \$1.1 million for the three-month period ended June 30, 2005. Cost of sales for the three-month period ended June 30, 2006 consisted of \$564,000 in inventory costs related to recognized revenue, \$549,000 in royalty fees, based on net product shipments, \$185,000 in amortization of intangible assets, an amount unrelated to either the volume of shipments or the amount of revenue recognized, and \$46,000 in period costs related to packaging, freight, and stability testing. Cost of sales for the three-month period ended June 30, 2005 consisted of \$732,000 in royalty fees, \$141,000 in inventory costs related to recognized revenue, \$130,000 in costs related to packaging, freight, and stability testing and \$83,000 in amortization of intangible assets. Payments to and interest expense related to our Paul Royalty Fund transaction discussed below in the section entitled *Liquidity and Capital Resources* does not impact our cost of sales.

### *Research and Development*

Research and development expenses for the three-month period ended June 30, 2006 were \$3.0 million as compared to \$5.0 million for the three-month period ended June 30, 2005, a decrease of approximately \$2.0 million, or 40%. The decrease in research and development expenses was primarily due to a decrease in expenses related to the termination of the valroceamide collaboration agreement in June 2005. The MS clinical development program expense increased from \$614,000 for the three-month period ended June 30, 2005 to \$1.7 million for the three-month period ended June 30, 2006, an increase of \$1.1 million or 185%, due to the continuation of increased activity in our Phase 3 clinical trial program.

Other contract expenses decreased to \$202,000 in the three-month period ended June 30, 2006, from \$3.1 million in the three-month period ended June 30, 2005, a decrease of \$2.9 million or 94%. This decrease was primarily due to a decrease in expenses related to the termination of the valroceamide collaboration agreement in June 2005. Operating expenses for clinical development and preclinical research and development was \$1.0 million for the three-month period ended June 30, 2006, compared to \$1.1 million in the three-month period ended June 30, 2005, a decrease of \$103,000 or 9%.

### *Sales and Marketing*

Sales and marketing expenses for the three-month period ended June 30, 2006 were \$4.3 million compared to \$3.1 million for the three-month period ended June 30, 2005, an increase of \$1.2 million or 40%. This increase was primarily attributable to an increase in salaries and benefits of \$501,000 and other selling related expenses of \$386,000 resulting from the expansion of our Zanaflex Capsules specialist sales force. In addition, marketing and distribution and sales administration expense related to the launch of Zanaflex Capsules and the distribution of Zanaflex tablets increased by \$328,000.

### *General and Administrative*

General and administrative expenses for the three-month period ended June 30, 2006 were \$3.6 million compared to \$1.8 million for the three-month period ended June 30, 2005, an increase of approximately \$1.8 million or 95%. The increase was primarily attributable to the addition of a Medical and Regulatory Affairs department with \$877,000 of related expenses. General and administrative staff

and salaries increased \$404,000, insurance expense increased by approximately \$254,000 and other third party services increased by \$189,000 resulting from our initial public offering.

*Other Income (Expense)*

Other income (expense) was expense of \$292,000 for the three-month period ended June 30, 2006 compared to expense of \$222,000 for the three-month period ended June 30, 2005. Interest expense increased by \$233,000 principally due to interest expense related to the sale of revenue interest to Paul Royalty Fund in December 2005, partially offset by a \$163,000 increase in interest income due to an increase in cash balances resulting from the completion of our initial public offering of common stock in February 2006.

*Beneficial Conversion Feature, Accretion of Issuance Costs, Preferred Dividends and Fair Value of Warrants Issued to Convertible Preferred Stockholders*

Charges related to preferred stock decreased from \$6.0 million for the three-month period ended June 30, 2005, to no charge for the three-month period ended June 30, 2006, due to the recognition of the remaining unamortized portion of beneficial conversion charges and issuance costs and reversal of the cumulative preferred dividend upon our completion of our initial public offering of our common stock in February 2006. No further charges are necessary.

*Six-Month Period Ended June 30, 2006 Compared to June 30, 2005*

*Gross Sales*

We recognized revenue from the sale of Zanaflex Capsules and Zanaflex tablets of \$11.8 million for the six-month period ended June 30, 2006, as compared to \$478,000 for the six-month period ended June 30, 2005. We recognize product sales using a deferred revenue recognition model meaning that shipments to wholesalers are recorded as deferred revenue and only recognized as revenue when end-user prescriptions of the product are reported. During the six-month period ended June 30, 2006, we adopted IMS Heath data as the prescription data source used as the basis for recognizing shipments of Zanaflex product as revenue. Included in gross sales for the six-month period ended June 30, 2006 is an additional \$621,000 resulting from the change in data vendors.

As part of the Zanaflex acquisition, the Company purchased certain tablet inventory from Elan that expired within one year. The majority of this product was sold by the Company during July 2004 through March 2005. The Company deferred revenue for this product due to the uncertainty of future returns. The Company received returns of the product sold by Elan through June 2006 at which point the right of return expired and the Company recognized the \$2.2 million deferred revenue balance as gross sales.

Gross sales in the six-month period ended June 30, 2005 consisted of Zanaflex tablet revenue recognized based on gross prescription data which we began receiving in March 2005, which is when we began receiving prescription data for tablets containing a code clearly identifying these prescriptions as having been filled with product we sold. We did not recognize revenue from Zanaflex Capsules prescription data until after our launch of the product in April 2005.

*Discounts and Allowances*

We recorded negative discounts and allowances of \$1.3 million for the six-month period ended June 30, 2006 as compared to \$844,000 for the six-month period ended June 30, 2005. As part of the Zanaflex acquisition in 2004, we agreed to accept any returns of Zanaflex tablets that were returned subsequent to January 17, 2005, including returns of product that was originally sold by Elan. Product returns prior to that date were the responsibility of Elan. As a result of this agreement, in December 2004 we recorded a return liability of \$4.1 million which was our best estimate of the Zanaflex tablet returns for



which we could potentially become liable. Our obligation to continue to accept these returns ended in June 2006. As a result of the returns we accepted since 2004, the net balance remaining on this liability was approximately \$1.8 million. We reversed this liability in June which resulted in a reduction in discounts and allowances of \$1.8 million and a corresponding reduction of the product return liability on our balance sheet.

Discounts and allowances are recorded when Zanaflex Capsules and Zanaflex tablets are shipped to wholesalers. Discounts and allowances for the six-month period ended June 30, 2006 consisted of a negative \$1.8 million due to the Elan product return liability reversal described above, \$232,000 in cash discounts and \$232,000 in allowances for chargebacks and rebates. Discounts and allowances for the six-month period ended June 30, 2005, consisted of \$597,000 in cash discounts and allowances of \$247,000 for chargebacks and rebates.

#### *Grant Revenue*

Grant revenue for the six-month period ended June 30, 2006 was \$301,000 compared to \$155,000 for the six-month period ended June 30, 2005. Grant revenue is recognized when the related research expenses are incurred and our performance obligations under the terms of the respective contract are satisfied.

#### *Cost of Sales*

We recorded cost of sales of \$2.4 million for the six-month period ended June 30, 2006 as compared to \$1.6 million for the six-month period ended June 30, 2005. Cost of sales for the six-month period ended June 31, 2006 consisted of \$984,000 in inventory costs related to recognized revenue, \$895,000 in royalty fees, based on net product shipments, \$370,000 in amortization of intangible assets, an amount unrelated to either the volume of shipments or the amount of revenue recognized, and \$136,000 in period costs related to packaging, freight, and stability testing. Cost of sales for the six-month period ended June 30, 2005 consisted of \$997,000 in royalty fees, \$205,000 in inventory costs related to recognized revenue, \$199,000 in costs related to packaging, freight, and stability testing and \$166,000 in amortization of intangible assets. Payments to and interest expense related to our Paul Royalty Fund transaction discussed below in the section entitled Liquidity and Capital Resources does not impact our cost of sales.

#### *Research and Development*

Research and development expenses for the six-month period ended June 30, 2006 were \$6.3 million as compared to \$7.1 million for the six-month period ended June 30, 2005, a decrease of approximately \$845,000, or 12%. The decrease in research and development expenses was primarily due to a decrease in expenses related to the termination of the valroceamide collaboration agreement in June 2005. The MS clinical development program expense increased from \$1.0 million for the six-month period ended June 30, 2005 to \$3.8 million for the six-month period ended June 30, 2006, an increase of \$2.8 million or 265%, due to the continuation of increased activity in our Phase 3 clinical trial program.

Other contract expenses decreased to \$357,000 in the six-month period ended June 30, 2006, from \$3.6 million in the six-month period ended June 30, 2005, a decrease of \$3.2 million or 90%. This decrease was primarily due to a decrease in expenses related to the termination of the valroceamide collaboration agreement in June 2005. Operating expenses for clinical development and preclinical research and development was \$2.1 million for the six-month period ended June 30, 2006, compared to \$2.3 million in the six-month period ended June 30, 2005, a decrease of \$256,000 or 11%.

*Sales and Marketing*

Sales and marketing expenses for the six-month period ended June 30, 2006 were \$8.8 million compared to \$5.4 million for the six-month period ended June 30, 2005, an increase of \$3.5 million or 65%. This increase was primarily attributable to an increase of \$1.3 million for marketing and distribution and sales administration expense related to the launch of Zanaflex Capsules and the distribution of Zanaflex tablets. Salaries and benefits increased \$1.3 million and other selling related expenses increased \$937,000 resulting from the expansion of our Zanaflex Capsules specialist sales force. Sales and marketing expenses are expected to trend higher over the remainder of the year.

*General and Administrative*

General and administrative expenses for the six-month period ended June 30, 2006 were \$5.8 million compared to \$3.9 million for the six-month period ended June 30, 2005, an increase of approximately \$1.9 million or 48%. The increase was primarily attributable to the addition of a Medical and Regulatory Affairs department with \$1.2 million of related expenses. Insurance expense increased by approximately \$393,000 and general and administrative staff and salaries increased \$369,000 resulting from our initial public offering.

*Other Income (Expense)*

Other income (expense) was expense of \$331,000 for the six-month period ended June 30, 2006 compared to expense of \$261,000 for the six-month period ended June 30, 2005. Interest expense increased by \$388,000 principally due to interest expense related to the sale of revenue interest to Paul Royalty Fund in December 2005, partially offset by a \$315,000 increase in interest income due to an increase in cash balances resulting from the completion of our initial public offering of common stock in February 2006.

*Cumulative effect of change in accounting principle*

On January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards 123 (revised 2004), Share-Based Payment (SFAS 123R), which requires that the costs resulting from all share-based payment transactions be recognized in the financial statements at their fair values. We adopted SFAS 123R using the modified prospective application method under which the provisions of SFAS 123R apply to new awards and to awards modified, repurchased, or cancelled after the adoption date. Additionally, compensation cost for the portion of the awards for which the requisite service has not been rendered that are outstanding as of the adoption date is recognized in the consolidated statement of operations over the remaining service period after the adoption date based on the award's original estimate of fair value. Results for prior periods have not been restated. In connection with the adoption of SFAS No. 123R, the Company changed its method of recognizing the number of outstanding instruments for which the requisite service is not expected to be rendered from an actual basis to an estimate. This change resulted in the recognition of a cumulative effect of change in accounting principle as of January 1, 2006 of \$454,000 compared to none for the six-month period ended June 30, 2005. The cumulative effect adjustment represents the difference between compensation cost recognized through the date of adoption using actual forfeitures and the cost that would have been recognized to date using estimated forfeitures.

*Beneficial Conversion Feature, Accretion of Issuance Costs, Preferred Dividends and Fair Value of Warrants Issued to Convertible Preferred Stockholders*

Charges related to preferred stock increased from \$12.2 million for the six-month period ended June 30, 2005, to \$36.0 million for the six-month period ended June 30, 2006, due to the recognition of the remaining unamortized portion of beneficial conversion charges of \$48.5 million and issuance costs of \$271,000 upon our completion of our initial public offering of our common stock in February 2006. These charges primarily comprised accretion of issuance costs on Series E, Series I and Series J mandatorily

redeemable convertible preferred stock, accrual of preferred dividend of on Series J and Series K mandatorily redeemable convertible preferred stock, accretion of beneficial conversion feature on Series A through Series I preferred stock for reset in conversion price, accretion of beneficial conversion feature on Series J preferred stock (see Notes 3 and 4 to our consolidated financial statements). These charges were partially offset by the reversal of the cumulative preferred dividends of \$12.7 million on Series J and Series K mandatorily redeemable convertible preferred stock during the six-month period ended June 30, 2006 as they have been forfeited through completion of the initial public offering.

### **Liquidity and Capital Resources**

We have incurred annual operating losses since inception, and, as of June 30, 2006, we had an accumulated deficit of approximately \$217.9 million. We have financed our operations primarily through private placements of our securities, and, to a lesser extent, from loans, government grants and, more recently, our financing arrangement with PRF and the completion of our initial public offering of our common stock in February 2006.

Our initial public offering resulted in the issuance of approximately 6.1 million shares of our common stock and the conversion of all our outstanding convertible and mandatorily convertible preferred stock. In connection with the offering of common shares, we raised approximately \$31.5 million, net of underwriter and other offering fees.

#### *Financing Arrangements*

Since our inception, we have raised aggregate net proceeds of \$159.2 million through private placements of equity securities. In January 1997, Elan International Services, Ltd. (EIS) loaned us an aggregate of \$7.5 million pursuant to two convertible promissory notes to partly fund our research and development activities, all of which was outstanding as of June 30, 2006. In August and September 2002, we financed certain of our fixed assets through two financing agreements with General Electric Capital Corporation, or GE Capital, in the aggregate amount of approximately \$1.2 million, of which \$42,000 was outstanding as of June 30, 2006. In January 2005, we entered into a \$6.0 million senior secured term loan, which is collateralized by all of our personal property and fixtures, other than the property that secures our revenue interests assignment arrangement with PRF, of which \$1.7 million was outstanding as of June 30, 2006. On December 23, 2005, we entered into a revenue interests assignment agreement with PRF, a dedicated healthcare investment fund, pursuant to which we assigned to PRF the right to a portion of our net revenues (as defined in the agreement) from Zanaflex Capsules, Zanaflex tablets and any future Zanaflex products.

#### *Investment Activities*

At June 30, 2006, cash and cash equivalents and short-term investments were approximately \$24.2 million, as compared to \$13.8 million at December 31, 2005. Our cash and cash equivalents consist of highly liquid investments with original maturities of three months or less at date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions and high-quality government and investment grade corporate bonds. Also, we maintain cash balances with financial institutions in excess of insured limits. We do not anticipate any losses with respect to such cash balances. Our short-term investments consist of corporate debt securities with original maturities greater than three months and less than one year. Our balance in these investments was \$500,000 as of June 30, 2006, as compared to \$2.0 million as of December 31, 2005. As of June 30, 2006, our cash and cash equivalents were \$23.7 million, as compared to \$11.8 million as of December 31, 2005.

*Net Cash Used by Operations*

Net cash used by operations was \$19.3 million and \$12.2 million for the six-month periods ended June 30, 2006 and 2005, respectively. Cash used by operations for the six-month period ended June 30, 2006 was primarily attributable to a net loss of \$9.8 million, a decrease in accounts payable, accrued expenses and other current liabilities of \$7.1 million, a decrease in capsule deferred product revenue of \$3.0 million and a decrease in returns liability of \$1.8 million. Cash used in operations for the six-month period ended June 30, 2006, was partially offset by non-cash stock compensation expense of \$1.9 million and depreciation and amortization expense of \$855,000. Cash used by operations for the six-month period ended June 31, 2005 was primarily attributable to a net loss of \$18.5 million, an increase in inventory of \$2.8 million, an increase in accounts receivable of \$2.2 million and a decrease in returns liability of \$1.7 million. Cash used in operations for the six-month period ended June 30, 2005, was partially offset by an increase in capsule deferred product revenue of \$11.0 million and an increase in accounts payable, accrued expenses and other current liabilities of \$2.3 million.

*Net Cash Used in/Provided by Investing*

Net cash used in investing activities for the six-month period ended June 30, 2006, was \$1.2 million, primarily due to purchases of short term investments of \$5.5 million partially offset by \$7.0 million in net proceeds received from maturities of short-term investments. In addition, we purchased property and equipment of approximately \$260,000 in the six-month period ended June 30, 2006. Net cash provided by investing activities for the six-month period ended June 30, 2005, was \$2.2 million, primarily due to purchases of short-term investments of \$11.4 million partially offset by \$9.3 million in net proceeds received from maturities of short-term investments. In addition, we purchased property and equipment of approximately \$119,000 in the six-month period ended June 30, 2005.

*Net Cash Used in/Provided by Financing*

Net cash provided by financing activities for the six-month period ended June 30, 2006, was \$30.0 million, primarily due to \$31.5 of initial public offering proceeds, net of issuance costs, offset by \$1.0 million in repayments of revenue interest liability and \$492,000 in repayments of notes payable. Net cash provided by financing activities for the six-month period ended June 30, 2005, was \$5.8 million, primarily due to \$5.8 million from the issuance of notes payable.

*Future Capital Needs*

Our future capital requirements will depend on a number of factors, including the amount of revenue generated from sales of Zanaflex Capsules, the continued progress of our research and development activities, the timing and outcome of regulatory approvals, the amount and timing of milestone or other payments made under collaborative agreements, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights and the acquisition of licenses to new products or compounds. We expect to incur losses from operations for at least the next several years as we continue to expand our sales and marketing infrastructure and increase our marketing efforts to support the commercialization of Zanaflex Capsules, continue our clinical development of Fampridine-SR and advance our preclinical programs.

We believe our existing cash and cash equivalents and short-term investment, together with the net proceeds from our financing arrangement with PRF and our initial public offering, will be sufficient to fund our operating expenses, debt repayments and capital equipment requirements to July 1, 2007. To the extent our capital resources are insufficient to meet future operating requirements, we will need to raise additional capital or incur indebtedness to fund our operations. We may be unable to obtain additional debt or equity financing on acceptable terms, if at all. If adequate funds are not available, we may be required to curtail our sales and marketing efforts, delay, reduce the scope of or eliminate some of our

research and development programs or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.

### **Contractual Obligations and Commitments**

In January 2005, we entered into a \$6.0 million senior secured term loan with GE Capital. In December 2005, we used a portion of the initial payment we received under our revenue interest assignment arrangement with PRF to repay approximately \$3.0 million of this loan. We are required to pay monthly installments until February 2008, with interest-only payments for the first six months followed by principal and interest payments for the remaining 29 months. Interest is fixed at the rate of 9.93% per annum. The loan is secured by all of our personal property and fixtures, other than the property that secures our arrangement with PRF. The aggregate principal payments required subsequent to June 30, 2006 are \$1.7 million.

In 2002, we entered into two financing agreements with GE Capital for an aggregate amount of approximately \$1.2 million, to finance the purchase of certain property and equipment. One note is for \$766,781 and bears an annual fixed interest rate of 8.88%. The second note is for \$386,731 and bears an annual fixed interest rate of 8.57%. These financing arrangements are secured by certain of our property and equipment and do not include any debt covenants. We are required to pay monthly installments until October 2006. The aggregate principal payments required subsequent to June 30, 2006 are \$41,832 in 2006.

In January 1997, Elan loaned us an aggregate of \$7.5 million pursuant to two convertible promissory notes. On December 23, 2005, Elan transferred these promissory notes to funds affiliated with Saints Capital. One promissory note in the principal amount of \$5.0 million bears interest at a rate of 3% which began on the first anniversary of the note. The other promissory note in the amount of \$2.5 million is non-interest bearing. The unpaid principal of \$5.0 million note is convertible into 67,476 shares of our common stock. The \$2.5 million promissory note is convertible into 210,863 shares of our common stock. The notes contain repayment and conversion provisions which are triggered based upon the regulatory status of certain products and termination of the license agreement with Elan. Both promissory notes restrict our ability to incur indebtedness that is senior to the notes, subject to certain exceptions, including our revenue interests assignment arrangement with PRF.

Under our Zanaflex purchase agreement with Elan, we are obligated to make milestone payments to Elan of up to \$19.5 million based on cumulative gross sales of Zanaflex tablets and Zanaflex Capsules as defined in the agreement. As of June 30, 2006, we have made or accrued \$4.5 million of these milestone payments in the consolidated financial statements. We expect to reach the third milestone level in the fourth quarter 2006 which would trigger a \$5.0 million payment that would be payable in the first quarter 2007. There are additional future milestones that could result in payments by us to Elan of \$10.0 million. Under our Zanaflex supply agreement with Elan, we are required to provide to Elan an 18-month rolling forecast at the beginning of each month and a two-year forecast not later than July 1 of each year. We are bound to order one hundred percent of the forecast required quantities for each five month period immediately following each monthly forecast report. At June 30, 2006, the forecast requirement for the five month period following June 30, 2006 amounted to approximately \$450,000.

Under our Fampridine-SR license agreement with Elan, we are obligated to make milestone payments to Elan of up to \$15.0 million over the life of the contract and royalty payments as a percentage of product sales. Combined obligations of royalties and costs of goods as defined in the Fampridine-SR license agreement is approximately 20%. In addition, under our various other research, license and collaboration agreements we are obligated to make milestone payments of up to an aggregate of approximately \$16.8 million over the life of the contracts.

Under the terms of the employment agreement with our chief executive officer, Ron Cohen, we are obligated to pay severance under certain circumstances. If the employment agreement is terminated by us or by our chief executive officer for reasons other than for cause, we must pay (i) an amount equal to the base salary the chief executive officer would have received during the fifteen month period immediately following the date of termination, plus (ii) bonus equal to last annual bonus received by chief executive officer multiplied by a fraction, the numerator of which shall be the number of days in the calendar year elapsed as of the termination date and the denominator of which shall be 365.

Under the terms of the employment agreements with our chief scientific officer, Andrew Blight, our chief operating officer, Mary Fisher, our chief financial officer, David Lawrence and our general counsel, Jane Wasman, we are obligated to pay severance under certain circumstances. In the event we terminate our employment agreement with Dr. Blight, Ms. Fisher, Mr. Lawrence or Ms. Wasman without cause, or if one of them voluntarily terminates his or her agreements with good reason, we are obligated to make severance payments equal to nine months base annual salary, in the case of Dr. Blight and Ms. Fisher, and seven months base annual salary, in the case of Mr. Lawrence and Ms. Wasman, as well as COBRA premium payments for the severance period. In such event, all options, stock appreciation rights awards and restricted stock awards that have vested as of the termination date shall remain exercisable for 90 days following such date. All unvested options, stock appreciation rights awards and stock awards will be cancelled on the date of termination. If Dr. Blight, Ms. Fisher, Mr. Lawrence or Ms. Wasman voluntarily terminates his or her employment without good reason or if we terminate his or her employment without cause within 18 months after a change in control, we are obligated to make severance payments equal to one year's base annual salary, in the case of Dr. Blight and Ms. Fisher, and nine months base annual salary, in the case of Mr. Lawrence and Ms. Wasman, in each case paid in a lump sum within 30 days after termination, as well as COBRA premium payments for the severance period plus a bonus equal to the prior year's bonus pro rated for the number of days worked prior to termination. We are also obligated to pay salary earned but not paid, vacation and sick leave days that have accrued, and reimbursable business expenses incurred through the date of termination. In such event, not less than 50% of the unvested options, stock appreciation rights and restricted or other stock awards shall become immediately and full vested and shall remain exercisable for 18 months following such date. All options that have vested as of the termination date shall remain exercisable for 90 days following such date. All unvested options, stock appreciation rights awards and stock awards will be cancelled on the date of termination.

#### **Critical Accounting Policies and Estimates**

The following discussion of critical accounting policies identifies the accounting policies that require application of management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. It is not intended to be a comprehensive list of all of our significant accounting policies, which are more fully described in Note 2 of the notes to the consolidated financial statements included in this prospectus. In many cases, the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles, with no need for management's judgment in their application. There are also areas in which the selection of an available alternative policy would not produce a materially different result. We have identified the following as our areas of critical accounting policies: sales revenue recognition, research and development, income taxes, and stock-based compensation.

#### **Revenue Recognition**

We apply the revenue recognition guidance in SFAS No. 48, *Revenue Recognition When the Right of Return Exists*, which among other criteria requires that future returns can be reasonably estimated in order to recognize revenue. Under SFAS No. 48 we are not permitted to recognize revenue until we can reasonably estimate the likely return rate for our products. Since we have only limited sales history with Zanaflex Capsules and due to generic competition and customer conversion from Zanaflex tablets to

Zanaflex Capsules, we do not believe we can reasonably determine a return rate. As a result, we account for sales of these products using a deferred revenue recognition model. At a future point in time, which could be in a number of years, when we are able to reasonably estimate product returns we will begin to recognize revenue based on shipments of product to our wholesale drug distributors.

Under our deferred revenue model, we do not recognize revenue upon shipment of product to our wholesale drug distributors. Instead, we record deferred revenue at gross invoice sales price, and classify the cost basis of the inventory shipped as inventory held by others. We recognize revenue when prescriptions are filled to an end-user because once a prescription is filled the product cannot be returned. We use monthly prescription data that we purchase to determine the amount of revenue to be recognized. We estimate prescription sales until the data becomes available, at which time adjustments are made to revenue and cost of sales to account for any differences between our estimates and the actual data. To date such differences have been minimal. The estimated prescription sales are based on average previous two month's prescriptions. Gross sales data reported in the financial statements in this filing are based on five months of actual prescription data and one month of estimated prescription data. The method for estimating prescriptions will be reevaluated as more prescription data becomes available. When we receive the prescription data, we use the number of units of product prescribed to record gross sales. We then reduce deferred revenue and record cost of goods sold. We began receiving end-user prescription data in March 2005 which enabled us to begin recognizing revenue from Zanaflex tablet sales. We began marketing Zanaflex Capsules in April 2005 and began receiving prescription data and recognizing revenue in the same month.

During the three-month period ended June 30, 2006 we adopted IMS Health data as the prescription data source used as the basis for recognizing shipments of Zanaflex product as revenue in lieu of a former prescription data provider. In addition to the prescription data we receive from IMS, we also receive data that we use to monitor trends in sales from wholesalers to their customers. We receive this data from an outside vendor on a monthly basis. This data includes the number of bottles shipped from certain wholesalers to their customers. We also compare our shipments to wholesalers to prescription reports to further assess inventory in the distribution channel on a monthly basis. We use the wholesaler sales trend data and the wholesaler vs. prescription comparison to better understand market conditions, but not as a basis for recognizing revenue.

We accept returns of products for six months prior to and 12 months after their expiration date. Returns of products sold by us are charged directly against deferred revenue, reducing the amount of deferred revenue that we may recognize.

#### *Sale of Zanaflex Tablet Inventory Acquired From Elan*

When we acquired Zanaflex from Elan, we also acquired Elan's inventory of Zanaflex tablets. This inventory included partial lots with expiration dating of less than 12 months and full lots with expiration dating greater than 12 months. We deferred recognition of any revenue from sales of the partial lot inventory until the return period for this product expired in June 2006, and recognized revenue only to the extent that deferred revenues exceeded returns. We could not use prescription data to recognize revenue associated with the partial lot inventory acquired from Elan because we cannot determine whether the prescription was filled with product that Elan sold prior to our acquisition of Zanaflex or with product we sold.

All Zanaflex tablet partial lot inventory that we acquired from Elan had either been sold or is no longer being sold by us. As a result, after the return period expired in June 2006, there was no longer be deferred revenue associated with the Zanaflex tablet partial lot inventory acquired from Elan.

In July 2005 we began to recognize revenue from the full lots based on prescriptions filled for Zanaflex tablets. All of the Zanaflex tablet inventory sold by Elan prior to our acquisition reached

expiration in June 2005, therefore any prescriptions filled for Zanaflex tablets subsequent to June 2005 must be from the full inventory lots acquired by and sold by us.

We were uncertain about the amount of returns that we may have received on these products, for a number of reasons including our limited historical returns experience. Returns of Zanaflex tablet inventory acquired from Elan and sold by us was charged against deferred revenue, reducing the amount of deferred revenue that we ultimately recognized during the three-month period ended June 30, 2006.

At June 30, 2006 we had deferred revenue from Zanaflex tablets of \$8.5 million. At December 31, 2005 we had deferred revenue from Zanaflex tablets of \$11.5 million, of which \$2.3 million was related to product acquired from Elan that had an expiration date of less than 12 months at the time it was sold during 2004. The Company received returns of the product sold by Elan through June 2006 at which point the right of return expired and the company recognized the \$2.2 million deferred revenue balance as gross sales.

#### *Returns of Zanaflex Tablets sold by Elan*

As part of the acquisition of Zanaflex, we agreed to accept any returns of Zanaflex tablets that were returned subsequent to January 17, 2005, including returns of product that was originally sold by Elan. Product returns prior to January 17, 2005, were the responsibility of Elan. We recorded a charge of \$4.1 million in the year ended December 31, 2004, for the estimated returns of Zanaflex tablets sold by Elan. The Company continued to receive returns of the product sold by Elan through June 2006 at which point the right of return expired and the remaining \$1.8 million accrual balance was reversed through discounts and allowances.

### **Research and Development**

Research and development expenses include the costs associated with our internal research and development activities including, salaries and benefits, occupancy costs, and research and development conducted for us by third parties, such as sponsored university-based research, and clinical trial vendors. In addition, research and development expenses include expenses related to grant revenue and the cost of clinical trial drug supply shipped to our clinical study vendors. We account for our clinical study costs by estimating the patient cost per visit in each clinical trial and recognizing this cost as visits occur, beginning when the patient enrolls in the trial. This estimated cost includes payments to the trial site and patient-related costs, including laboratory costs related to the conduct of the trial. Cost per patient varies based on the type of clinical trial, the site of the clinical trial, and the length of the treatment period for each patient. As actual costs become known to us, we adjust our accrual; such changes in estimate may be a material change in our clinical study accrual, which could also materially affect our results of operations.

### **Income Taxes**

As part of the process of preparing our financial statements we are required to estimate our income taxes in each of the jurisdictions in which we operate. We account for income taxes by the liability method. Under this method, deferred income taxes are recognized for tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end, based on enacted laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

We have not recorded any tax provision or benefit for the six-month periods ended June 30, 2006 and 2005. We have provided a valuation allowance for the full amount of our net deferred tax assets since realization of any future benefit from deductible temporary differences and net operating loss carry-forwards cannot be sufficiently assured at June 30, 2006.



As of June 30, 2006, we had available net operating loss carry-forwards of approximately \$143.9 million for federal and state income tax purposes, which are available to offset future federal and state taxable income, if any, and expire between 2010 and 2025 and research and development tax credit carry-forwards of approximately \$1.2 million for federal income tax reporting purposes which are available to reduce federal income taxes, if any, through 2018. Since our inception, we have incurred substantial losses and expect to incur substantial and recurring losses in future periods. The Internal Revenue Code of 1986, as amended, the Code, provides for a limitation of the annual use of net operating loss and research and development tax credit carry forwards (following certain ownership changes, as defined by the Code) that could significantly limit our ability to utilize these carry-forwards. We have experienced various ownership changes, as defined by the Code, as a result of past financings. Accordingly, our ability to utilize the aforementioned carry-forwards may be limited. Additionally, because U.S. tax laws limit the time during which these carry forwards may be applied against future taxes we may not be able to take full advantage of these attributes for federal income tax purposes.

### **Stock-Based Compensation**

Historically, the Company accounted for share-based compensation costs under the provisions of Statement of Financial Accounting Standards 123 (SFAS No. 123), *Accounting for Stock-Based Compensation*, using a fair-value-based method of accounting for stock-based employee compensation plans.

On January 1, 2006, the Company adopted the provisions of Statement of Financial Accounting Standards 123 (revised 2004), *Share-Based Payment* (SFAS No. 123R), which requires that the costs resulting from all share-based payment transactions be recognized in the financial statements at their fair values. The Company adopted SFAS No. 123R using the modified prospective application method under which the provisions of SFAS No. 123R apply to new awards and to awards modified, repurchased, or cancelled after the adoption date. Additionally, compensation cost for the portion of the awards for which the requisite service has not been rendered that are outstanding as of the adoption date is recognized in the Consolidated Statement of Operations over the remaining service period after the adoption date based on the award's original estimate of fair value. Results for prior periods have not been restated.

In connection with the adoption of SFAS No. 123R, the Company changed from recognizing the effect of forfeitures as they occur to estimating the number of outstanding instruments for which the requisite service is not expected to be rendered. Prior to the adoption of SFAS No. 123R, the Company recognized forfeitures associated with its share-based awards as they occurred rather than estimating forfeitures. Upon adoption of SFAS No. 123R, the Company recorded a cumulative effect of change in accounting principle of \$454,225 during the three-month period ended March 31, 2006, calculated as the difference between compensation cost recognized to date using actual forfeitures and the cost that would have been recognized to date using estimated forfeitures. The Company estimates that its future annual forfeiture rate will be 5%.

The Company accounts for stock options granted to non-employees on a fair-value basis in accordance with EITF No. 96-18, *Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services*, and FASB Interpretation No. 28, *Accounting for Stock Appreciation Rights and Other Variable Stock Option or Award Plans an Interpretation of APB Opinion No. 15 and 25*.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Our financial instruments consist of cash and cash equivalents, short-term investments, grant receivable, notes payable, convertible notes payable, accounts payable, warrant liability, and put/call liability. The estimated fair values of all of our financial instruments, excluding convertible notes payable to Saints Capital, approximate their carrying amounts at June 30, 2006.

We have cash equivalents and short-term investments at June 30, 2006, which are exposed to the impact of interest rate changes and our interest income fluctuates as our interest rates change. Due to the short-term nature of our investments in money market funds and corporate debt securities, the carrying value of our cash equivalents and short-term investments approximate their fair value at June 30, 2006.

We maintain an investment portfolio in accordance with our investment policy. The primary objectives of our investment policy are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. Although our investments are subject to credit risk, our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure from any single issue, issuer or type of investment. Our investments are also subject to interest rate risk and will decrease in value if market interest rates increase. However, due to the conservative nature of our investments and relatively short duration, interest rate risk is mitigated. We do not own derivative financial instruments. Accordingly, we do not believe that there is any material market risk exposure with respect to derivative or other financial instruments.

#### **Item 4. Controls and Procedures.**

##### ***Evaluation of disclosure controls and procedures***

As required by Rule 13a-15 under the Exchange Act, within 90 days prior to filing this report, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. This evaluation was carried out under the supervision and with the participation of our management, including our chief executive officer and our chief financial officer. Based on that evaluation, these officers have concluded that, as of June 30, 2006, our disclosure controls and procedures were effective and designed to ensure that material information relating to us required to be included in our reports filed under the Exchange Act would be made known to them.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and regulations. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding disclosure.

##### ***Change in internal control over financial reporting***

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2006 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

##### ***Limitations on the effectiveness of controls***

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

## **PART II OTHER INFORMATION**

### **Item 1. Legal Proceedings.**

We are not currently a party to any material legal proceedings.

### **Item 1A. Risk Factors**

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2005 and our Form 10-Q for the three-month period ended March 31, 2006, all of which could materially affect our business, financial condition or future results. The risks described in the Annual Report and Form 10-Q for the three-month period ended March 31, 2006 are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

### **Item 6. Exhibits**

- 31.1 Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
- 31.2 Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
- 32.1 Certification pursuant to 18 USC. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

II-1

---

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Acorda Therapeutics, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York State of New York, on this 11th day of August 2006.

**Acorda Therapeutics, Inc.**

By: /s/ Ron Cohen  
Ron Cohen  
President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Ron Cohen Ron Cohen, M.D.	President, Chief Executive Officer and Director (Principal Executive Officer)	August 11, 2006
/s/ David Lawrence David Lawrence, M.B.A.	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	August 11, 2006

II-2

---

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
31.1	Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
31.2	Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
32.1	Certification pursuant to 18 USC. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

II-3

---